{"entity":{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","aka":["MAPKeeper 301"],"tldr":"A phase 3 trial testing Atebimetinib in pancreatic ductal adenocarcinoma, now recruiting.","summary":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07562152, led by Immuneering, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301). Planned enrolment is 510 participants (estimated). The study started in 2026-06-05 and primary completion is expected in 2028-06. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07562152","url":"https://clinicaltrials.gov/study/NCT07562152"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["atebimetinib"],"companies":["immuneering"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07562152","phase":"3","setting":"A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","sponsor":"Immuneering","started":"2026-06-05","startedType":"actual","enrolled":510,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07562152/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/"}],"company":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/"}]}}